Limitations of the study include its retrospective nature, potential immortal time bias in the subgroup OS estimate for brain metastasis at any time, lower than expected frequency of brain metastases compared to other retrospective series in patients with KRAS G12C mutant NSCLC,10,13–15 and that patient numbers among those treated with docetaxel were limited as all patients were treated in academic medical centers and more often enrolled in clinical trials in the relapsed NSCLC setting. This evidence concerns the gene KRAS and non-small cell lung carcinoma.